http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2228335-C2
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-02 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00 |
| filingDate | 1997-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2004-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ea52ea0a4a4a625ef8495885e4b6f34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a139ff503fd4e9723c6f70016da47c58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_538dfd3a7555ae3280ef8826758dc032 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba8868a527d7c16e8af0b0166b282622 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cad09da9ea6139de656db9836bb91779 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b7495b27798a21713f580d94198eba1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a700c1aff25f2442dfe252be2ac8365a |
| publicationDate | 2004-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2228335-C2 |
| titleOfInvention | Substituted derivatives of purine, methods for their preparing and pharmaceutical preparation |
| abstract | FIELD: organic chemistry, heterocyclic compounds, chemical technology, medicine, pharmacy. SUBSTANCE: invention relates to new compounds of formulas (I) and (Ia) in their all stereoisomeric forms or their mixtures in all ratios, and their pharmaceutically acceptable salts eliciting antagonistic activity with respect to vitronectin receptors. Compounds can be used as inhibitors of osseous resorption by osteoclasts, tumor growth or tumor metastatic spreading and so on. Invention relates also to methods for preparing compounds of formulas (I) and (Ia) and to pharmaceutical composition based on thereof. There are following values in compounds of formulas (I) and (Ia): X means hydrogen atom, NR 6 R 6′ , fluorine, chlorine, bromine atom, OR 6 , SR 6 , hydroxy-(C 1 -C 6 )-alkyl-NH, [hydroxy-(C 1 -C 6 )-alkyl] 2 N,, amino-(C 1 -C 6 )-alkyl-NH, [amino-(C 1 -C 6 )-alkyl] 2 N,, hydroxy-(C 1 -C 6 )-alkyl-O, hydroxy-(C 1 -C 6 )-alkyl-S or NH-CO-R 6 ; Y means hydrogen atom; G means a residue of the formula (II): (CR 1 R 2 ) n -A-(CR 1 R 2 ) m -(CR 1 R 3 ) i -(CR 1 R 2 ) q -R 4 (II); W means a residue of the formula (III): -B-(CR 1 R 2 ) r -A′-(CR 1 R 2 ) s -(CR 1 R 2 ) k -(CR 1 R 2 ) t -D-E (III); G a means a residue of the formula (IIa): -(CR 1 R 2 ) r -A′-(CR 1 R 2 ) s -(CR 1 R 2 ) k -(CR 1 R 2 ) t -D-E (IIa); W a means a residue of the formula (IIIa): -B-(CR 1 R 2 ) n -A-(CR 1 R 2 ) m -(CR 1 R 3 ) i -(CR 1 R 2 ) q -R 4 (IIIa); A, A′ mean independently of one another a single bond, -C(O)NH- or NH-; R 1 , R 2 mean independently of one another hydrogen, fluorine, chlorine atoms, cyano-group, nitro-group, (C 1 -C 10 )-alkyl, (C 3 -C 14 )-cycloalkyl, (C 3 -C 14 )-cycloalkyl-(C 1 -C 8 )-alkyl, (C 5 -C 14 )-aryl, (C 1 -C 8 )-aryl-(C 1 -C 8 )-alkyl, or R 6 R 6′ N-R 7 ; R 3 means independently of one another hydrogen, fluorine, chlorine atom, cyano-group, nitro-group, (C 1 -C 18 )-alkyl, (C 3 -C 14 )-cycloalkyl, (C 3 -C 14 )-cycloalkyl-(C 1 -C 8 )-alkyl,(C 5 -C 14 )-aryl,(C 5 -C 14 )-aryl-(C 1 -C 8 )-alkyl, or R 6 N(R 6′ )S(O) p R 7 being alkyl can be mono- or multi-unsaturated and alkyl or aryl can be mono- or multi-substituted with fluorine, chlorine, bromine atom, cyano-group, R 6 R 6′ N-R 7 , nitro-group, or R 6 -O-R 7 ; R 4 means C(O)R 8 ; R 6 , R 6′ , R 5 mean independently of one another hydrogen atom (C 1 -C 10 )-alkyl, (C 3 -C 14 )-cycloalkyl, (C 3 -C 14 )-cycloalkyl-(C 1 -C 8 )-alkyl, (C 5 -C 14 )-aryl, (C 5 -C 14 )-aryl-(C 1 -C 8 )-alkyl; R 7 means independently of one another (C 1 -C 4 )-alkylene or a single bond; R 8 means hydroxy-group, (C 1 -C 8 )-alkoxy-group, (C 5 -C 14 )-aryl- -alkoxy-group, (C 5 -C 14 )-aryloxy-group, (C 1 -C 8 )-alkylcarbonyloxy-(C 1 -C 4 )-alkoxy-group, (C 5 -C 14 )-aryl- -(C 1 -C 8 )-alkylcarbonyloxy-(C 1 -C 8 )-alkoxy- group, NR 6 R 6′ , (di-((C 1 -C 8 )-alkyl)amino)-carbonylmethyloxy-group,(di-((C 5 -C 14 )-aryl-(C 1 -C 8 )-alkyl)amino)carbonylmethyloxy- group; B means an ordinary bond, NH, CONH, piperidinyl, sulfur atom or imidazole; D means a single bond, or -R 6 C=N-, or -R 6 C=N-NR 6 -, being bivalent residues meaning D through a free bond on the right side are bound with the group E wherein E means hydrogen atom, -NH- -CH(=NH), -C(=NH)-NH 2 or 5,6-membered aromatic or non-aromatic residue comprising optionally 1 or 2 nitrogen atoms and possibly substituted with oxo-group,, residue R 5 or R 3 or possibly condensed with phenyl group as benzimidazole residue; n = 0, 1, 2, 3, 4 or 5; m = 0, 1, 2, 3, 4 or 5; i = 0 or 1; p means independently of one another 0, 1 or 2; q = 0, 1 or 2; r = 0, 1, 2, 3, 4, 5 or 6; s = 0, 1, 2, 3, 4 or 5; t = 0, 1, 2, 3, 4 or 5; k = 0 or 1; u = 0 or 2; in their all stereoisomeric forms or their mixtures in all ratios and their pharmaceutically acceptable salts. EFFECT: improved preparing methods, valuable biological and medicinal properties of compounds. 12 cl, 1 tbl, 29 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9751944-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9079959-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9090692-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9815899-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2475499-C2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9114131-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8546540-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8575316-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9464133-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10723800-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10308715-B2 |
| priorityDate | 1996-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 393.